OMN6 – the Next-Generation of Antibiotic Drugs
OMN6 is a novel antimicrobial peptide developed for IV administration in hospitalized patients suffering from severe or life-threatening infections involving Multi-Drug-Resistant bacteria
OMN6 is effective and safe. Targeting a huge, urgent unmet need, OMN6 eliminates resistan
Technology:
Microorganisms:
Application:
- Infection prevention
- Antimicrobial compounds
- Alternative antimicrobials
Microorganisms:
- Bacteria
- Fungi
- Yeasts
Application:
- Human
- Veterinary
- AgriFood
- Environmental
Development stage:
Organization:
Partnering:
- Development
Organization:
- Company
Partnering:
- License, Co-develop, Joint Venture, Sell
Big-pharma or a strategic-player that has the experience and expertise to join us in bringing a life-saving antibiotic drug to the market
Omnix Medical is a privately-owned biotechnology company developing the next-generation antibiotics against Multi Drug Resistant bacteria
Omnix is developing a pipeline of anti-infective compounds at different stages of the development route